Search Results - "Barceló, I. Bover"

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial by Mirza, Mansoor R., Benigno, B., Dørum, A., Mahner, S., Bessette, P., Barceló, I. Bover, Berton-Rigaud, D., Ledermann, J.A., Rimel, B.J., Herrstedt, J., Lau, S., du Bois, A., Herráez, A. Casado, Kalbacher, E., Buscema, J., Lorusso, D., Vergote, I., Levy, T., Wang, P., de Jong, F.A., Gupta, D., Matulonis, U.A.

“…Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved for use in heavily pretreated patients and as maintenance treatment in patients with…”
Get full text

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR) by Sehouli, J., Chekerov, R., Reinthaller, A., Richter, R., Gonzalez-Martin, A., Harter, P., Woopen, H., Petru, E., Hanker, L.C., Keil, E., Wimberger, P., Klare, P., Kurzeder, C., Hilpert, F., Belau, A.K., Zeimet, A., Bover-Barcelo, I., Canzler, U., Mahner, S., Meier, W.

“…The combination of carboplatin and topotecan in platinum-sensitive relapsed ovarian cancer could not improve progression-free survival or overall survival…”
Get full text